Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.73 -5.9%	$0.77	$0.38 ▼ $115.57	$8.52M	0.71	1.58 million shs	55,781 shs
GRAY Graybug Vision	$2.73 -5.9%	$2.52	$5.00 ▼ $22.12	$4.29M	1.2	2,165 shs	26,030 shs
IBIO iBio	$0.82 -0.9%	$0.73	$0.56 ▼ $6.89	$16.07M	0.6	1.54 million shs	562,452 shs
MTNB Matinas Biopharma	$1.82 -10.8%	$1.19	$0.47 ▼ $4.49	$9.26M	1.32	437,605 shs	44,429 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	+1.01%	+12.72%	-0.03%	+35.03%	-98.87%
GRAY Graybug Vision	+3.94%	+5.45%	-23.68%	+64.77%	-32.24%
IBIO iBio	+2.23%	+6.29%	+19.60%	+7.50%	-57.03%
MTNB Matinas Biopharma	+3.03%	+17.24%	+133.41%	+151.23%	+998.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	2.9668 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.0	1.9
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.2679 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.0	0.6
MTNB Matinas Biopharma	0.6391 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	49,100.49% Upside
GRAY Graybug Vision	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	511.47% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRAY, IBIO, MTNB, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
GRAY Graybug Vision	N/A	N/A	N/A	N/A	$1.67 per share	N/A
IBIO iBio	$375K	42.86	N/A	N/A	$1.41 per share	0.58
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$6.08	4.07	N/A	N/A	N/A	N/A	-994.63%	N/A
GRAY Graybug Vision	-$35.60M	-$24.23	N/A	N/A	N/A	N/A	-77.61%	-71.34%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
GRAY Graybug Vision	N/A	10.73	10.72
IBIO iBio	0.05	1.76	1.76
MTNB Matinas Biopharma	N/A	5.53	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
GRAY Graybug Vision	49.94%
IBIO iBio	7.90%
MTNB Matinas Biopharma	11.77%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
GRAY Graybug Vision	7.94%
IBIO iBio	0.58%
MTNB Matinas Biopharma	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.64 million	74.37 million	Not Optionable
GRAY Graybug Vision	27	1.57 million	20.25 million	Not Optionable
IBIO iBio	100	19.66 million	9.82 million	N/A
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A

GRAY, IBIO, MTNB, and AEON Headlines

Recent News About These Companies

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum

June 7, 2025 | kalkinemedia.comK

Matinas BioPharma amends bylaws, updates on officer agreements

May 4, 2025 | investing.com

Matinas BioPharma files to sell 16.9M shares of common stock for holders

April 24, 2025 | markets.businessinsider.com

Matinas BioPharma secures shareholder nods on key proposals

April 6, 2025 | investing.com

Matinas BioPharma announces board chairman’s departure

March 16, 2025 | investing.com

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

March 11, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

March 11, 2025 | finance.yahoo.com

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

February 13, 2025 | globenewswire.com

Matinas BioPharma announces board member retirement

February 11, 2025 | msn.com

Matinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee Chair

February 9, 2025 | nasdaq.com

Matinas BioPharma appoints Evelyn D’An to board of directors

February 7, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

February 7, 2025 | finance.yahoo.com

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

February 7, 2025 | globenewswire.com

Matinas BioPharma announces board member resignation

January 25, 2025 | msn.com

111 Equity Group increases stake in Matinas BioPharma

January 24, 2025 | markets.businessinsider.com

111 Equity ups stake in Matinas Biopharma Holdings

January 24, 2025 | msn.com

111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.

January 24, 2025 | finance.yahoo.com

What Factors Have Led to Matinas BioPharma Holdings Inc (MTNB) Stock Trading -96.74% Below Its 52-Week High?

January 15, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY, IBIO, MTNB, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.73 -0.05 (-5.93%)

Closing price 03:59 PM Eastern

Extended Trading

$0.73 +0.00 (+0.04%)

As of 04:49 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Graybug Vision NASDAQ:GRAY

$2.73 -0.17 (-5.86%)

As of 08/28/2025

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

iBio NYSE:IBIO

$0.82 -0.01 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 +0.00 (+0.53%)

As of 05:26 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Matinas Biopharma NYSE:MTNB

$1.82 -0.22 (-10.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.83 +0.01 (+0.55%)

As of 05:27 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time